GlassScriptPhysician profile
Howard C Mandel
NPI 1245237437
$11,912.28
in general payments reported to CMS, 2019-2025
21 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $1,751 · 2021: $1,669 · 2022: $308 · 2023: $7,462 · 2024: $353 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,700 · Travel and Lodging: $2,323 · Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,700.00 |
| Travel and Lodging | $2,323.33 |
| Food and Beverage | $943.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,291.11 | 2019-2024 | |
| Therapeuticsmd, INC. | $1,624.03 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $1,344.94 | 2021 | |
| Mayne Pharma Commercial LLC | $562.29 | 2021-2025 | |
| Aspira Women'S Health INC | $356.03 | 2019-2023 | Ova1 |
| Abbvie INC. | $223.24 | 2019-2023 | |
| Astellas Pharma US INC | $87.50 | 2023-2025 | Veozah |
| Agile Therapeutics, INC. | $63.91 | 2021-2024 | Twirla |
| Becton, Dickinson and Company | $53.49 | 2022-2024 | Bd Onclarity |
| Exeltis, USA INC. | $43.51 | 2022-2024 | Slynd |
| Allergan, INC. | $37.96 | 2020 | |
| Cepheid | $31.41 | 2025 | Genexpert |
| Coopersurgical, INC. | $30.87 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $28.84 | 2023 | Vivjoa |
| Lupin INC. | $28.64 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2019 | |
| Myovant Sciences INC. | $20.89 | 2022 | |
| Sumitomo Pharma America, INC. | $19.26 | 2023 | Myfembree |
| Ascend Therapeutics US, LLC | $17.05 | 2021 | |
| Millicent US INC | $14.35 | 2025 | Intrarosa, Femlyv |
| Channel Medsystems, INC. | $11.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.